TY - JOUR
T1 - Assessing production variability in empty and filled adeno-associated viruses by single molecule mass analyses
AU - Ebberink, Eduard H T M
AU - Ruisinger, Alisa
AU - Nuebel, Markus
AU - Thomann, Marco
AU - Heck, Albert J R
N1 - Funding Information:
We thank Dr. Victor Yin for thorough reading of the manuscript and giving valuable input. For technical support we thank Ing. Arjan Barendregt. We also thank Dominik Kochardt for running the CE-SDS analyses. This work was performed in Utrecht in the Netherlands, with the CE-SDS analysis in Penzberg in Germany. A.J.R.H. acknowledges support from the Netherlands Organization for Scientific Research through a Spinoza Award (SPI.2017.028).
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/12/8
Y1 - 2022/12/8
N2 - Adeno-associated viruses (AAVs) are useful vehicles for gene therapy because of their stability, low immunogenicity. and non-pathogenicity. However, disparity in AAV sample preparations (e.g., in capsid composition, DNA packaging, and impurities) gives rise to product heterogeneity, with possibly undesired effects on gene delivery. Ideally, AAV production should be with full control of AAV structure and genetic payload. Therefore, robust, efficient, and low material consuming methods are essential to characterize AAVs. Here, we use two emerging single-molecule techniques, mass photometry and Orbitrap-based charge-detection mass spectrometry, and show how they may efficiently and accurately characterize AAVs. We were able to resolve heterogeneous pools of particles, evaluating AAVs from two different serotypes (AAV8 and AAV2), produced by three independent production platforms, either lacking a genome or packed with a transgene. Together our data confirm that the different AAV production methods result in rather different and diverse AAV particle distributions. Especially for the packed AAVs, frequently additional subspecies were observed, next to the expected packed genome, mostly resulting from under- or overpackaging of genome material and/or residual empty particles. This work further establishes that both these single-particle techniques may become valuable tools in characterizing AAVs before they are used in gene therapy.
AB - Adeno-associated viruses (AAVs) are useful vehicles for gene therapy because of their stability, low immunogenicity. and non-pathogenicity. However, disparity in AAV sample preparations (e.g., in capsid composition, DNA packaging, and impurities) gives rise to product heterogeneity, with possibly undesired effects on gene delivery. Ideally, AAV production should be with full control of AAV structure and genetic payload. Therefore, robust, efficient, and low material consuming methods are essential to characterize AAVs. Here, we use two emerging single-molecule techniques, mass photometry and Orbitrap-based charge-detection mass spectrometry, and show how they may efficiently and accurately characterize AAVs. We were able to resolve heterogeneous pools of particles, evaluating AAVs from two different serotypes (AAV8 and AAV2), produced by three independent production platforms, either lacking a genome or packed with a transgene. Together our data confirm that the different AAV production methods result in rather different and diverse AAV particle distributions. Especially for the packed AAVs, frequently additional subspecies were observed, next to the expected packed genome, mostly resulting from under- or overpackaging of genome material and/or residual empty particles. This work further establishes that both these single-particle techniques may become valuable tools in characterizing AAVs before they are used in gene therapy.
KW - AAV biomanufacturing
KW - AAV2
KW - AAV8
KW - Adeno-associated virus
KW - charge-detection mass spectrometry
KW - empty-filled ratio
KW - gene-delivery vector
KW - mass photometry
KW - native mass spectrometry
KW - single molecule mass analyses
UR - http://www.scopus.com/inward/record.url?scp=85143145086&partnerID=8YFLogxK
U2 - 10.1016/j.omtm.2022.11.003
DO - 10.1016/j.omtm.2022.11.003
M3 - Article
C2 - 36458114
SN - 2329-0501
VL - 27
SP - 491
EP - 501
JO - Molecular Therapy - Methods and Clinical Development
JF - Molecular Therapy - Methods and Clinical Development
ER -